Rezdiffra vs Motegrity
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Rezdiffra | US Motegrity | |
|---|---|---|
| Generic name | resmetirom | prucalopride |
| Drug class | Thyroid Hormone Receptor-Beta Agonist | Serotonin-4 Receptor Agonist |
| Treats | Metabolic dysfunction-associated steatohepatitis (MASH) | Chronic idiopathic constipation |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Madrigal Pharmaceuticals | Takeda |
| Year approved | 2024 | 2018 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Nausea, Itching, Gallbladder problems | Headache, Abdominal pain, Nausea, Diarrhea |
Rezdiffra
Motegrity
Frequently asked questions
Is Rezdiffra or Motegrity better?
Neither is universally "better." Rezdiffra (resmetirom) and Motegrity (prucalopride) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rezdiffra and Motegrity?
Rezdiffra is a Thyroid Hormone Receptor-Beta Agonist made by Madrigal Pharmaceuticals, while Motegrity is a Serotonin-4 Receptor Agonist made by Takeda. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rezdiffra has the larger estimated TV advertising budget of the two.